All In Biotech

Drug Trial Radar · NCT01433497

Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple Sclerosis

A 96 Week, Prospective, Multicentre, Randomized, Double-blind, Placebo-controlled, 2 Parallel-groups, Phase 3 Study to Compare Efficacy and Safety of Masitinib 4.5 mg/kg/Day Versus Placebo in the Treatment of Patients With Primary Progressive or Relapse-free Secondary Progressive Multiple Sclerosis

Last checked: Nov 19, 2026Latest source record: Apr 8, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 656 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

656

Actual

Start

Aug 2011

Primary completion

Sep 2019

Study completion Feb 2020

Sponsor

Lead sponsor
AB ScienceIndustry
Sponsor type
Industry
First posted
Sep 14, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the safety and efficacy of masitinib 6 mg/kg/day versus placebo in the treatment of patients with primary progressive multiple sclerosis or relapse-free secondary progressive multiple sclerosis.

Conditions

  • Multiple Sclerosis, Secondary Progressive
  • Multiple Sclerosis, Primary Progressive
  • Multiple Sclerosis, Relapse Free

Interventions

  • MasitinibDrug

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. EDSSTime frame: 96 weeks

Locations

8 sites in 7 countries. Site status is shown where the registry gives one.

  • "St. Ivan Rilski" University Multiprofile Hospital for Active Treatment

    Sofia, Bulgaria

  • GHICL hopital ST vincent de Paul

    Lille, France

  • Hôpital de Gui de Chauliac

    Montpellier, France

  • Universitätsklinikum Gießen und Marburg

    Marburg, Germany

  • Rehibilitation Center "KENTAVROS"

    Volos, Greece

  • KO-MED Centra Kliniczne Lublin II

    Lublin, Poland

  • Centrul Medical Clubul Sănătăţii

    Campulung Muscel, Romania

  • Hospital de la Santa Creu i Sant Pau

    Barcelona, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.